|

Pembrolizumab 25 MG/ML [Keytruda] Clinical Trials

2 actively recruiting trials

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Maria Sklodowska-Curie National Research Institute of Oncology1
  • Imperial College London1

Indications

  • Cancer2
  • Adrenocortical Carcinoma1
  • Lung Cancer, Nonsmall Cell1
  • Lung Cancer1

Other2 trials

A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 3
Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.